SRB1
Inflammatory Diseases
Key Facts
About SunRock Biopharma
SunRock Biopharma is a private, preclinical-stage biotech focused on developing novel antibodies for oncology, with a core expertise in targeting chemokine receptor CCR9 and the HER3 (ERBB3) pathway. The company has established a pipeline of mono- and bi-specific antibodies, with several HER3-targeting assets already licensed to Debiopharm, providing non-dilutive funding and validation. SunRock's strategy centers on addressing tumor metastasis and therapy resistance, positioning it in the competitive but high-value oncology biologics space.
View full company profileAbout SunRock Biopharma
SunRock Biopharma is a private, preclinical-stage biotech focused on developing novel antibodies for oncology, with a core expertise in targeting chemokine receptor CCR9 and the HER3 (ERBB3) pathway. The company has established a pipeline of mono- and bi-specific antibodies, with several HER3-targeting assets already licensed to Debiopharm, providing non-dilutive funding and validation. SunRock's strategy centers on addressing tumor metastasis and therapy resistance, positioning it in the competitive but high-value oncology biologics space.
View full company profileTherapeutic Areas
Other Inflammatory Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Amilo-5MER | Galmed Pharmaceuticals | Preclinical |
| Biosimilar to Simponi® (golimumab) | Teva | Under Regulatory Review |
| Fbxo3 Inhibitor Program | Koutif Therapeutics | Pre-clinical |
| CPR‑CYC‑202 | Chugai Pharmabody Research | Preclinical |
| Follow-on Compounds | Abivax | Research |
| CDX-622 | Celldex Therapeutics | Phase 1 |
| Avdoralimab (IPH5401) | Innate Pharma | Phase 2 |
| Izicopan (IFX-4) | InflaRx | Preclinical |
| IFX002 | InflaRx | Preclinical |